key: cord-0930246-gfskwmh4
authors: Dagens, Andrew; Sigfrid, Louise; Cai, Erhui; Lipworth, Sam; Cheung, Vincent; Harris, Eli; Bannister, Peter; Rigby, Ishmeala; Horby, Peter
title: Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review
date: 2020-05-26
journal: BMJ
DOI: 10.1136/bmj.m1936
sha: 2307fe5df2ad994dcbc55435a275f3fb2a6aa5dd
doc_id: 930246
cord_uid: gfskwmh4

OBJECTIVE: To appraise the availability, quality, and inclusivity of clinical guidelines produced in the early stage of the coronavirus disease 2019 (covid-19) pandemic. DESIGN: Rapid review. DATA SOURCES: Ovid Medline, Ovid Embase, Ovid Global Health, Scopus, Web of Science Core Collection, and WHO Global Index Medicus, searched from inception to 14 Mar 2020. Search strategies applied the CADTH database guidelines search filter, with no limits applied to search results. Further studies were identified through searches of grey literature using the ISARIC network. INCLUSION CRITERIA: Clinical guidelines for the management of covid-19, Middle East respiratory syndrome (MERS), and severe acute respiratory syndrome (SARS) produced by international and national scientific organisations and government and non-governmental organisations relating to global health were included, with no exclusions for language. Regional/hospital guidelines were excluded. Only the earliest version of any guideline was included. QUALITY ASSESSMENT: Quality was assessed using the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool. The quality and contents of early covid-19 guidelines were also compared with recent clinical guidelines for MERS and SARS. RESULTS: 2836 studies were identified, of which 2794 were excluded after screening. Forty two guidelines were considered eligible for inclusion, with 18 being specific to covid-19. Overall, the clinical guidelines lacked detail and covered a narrow range of topics. Recommendations varied in relation to, for example, the use of antiviral drugs. The overall quality was poor, particularly in the domains of stakeholder involvement, applicability, and editorial independence. Links between evidence and recommendations were limited. Minimal provision was made for vulnerable groups such as pregnant women, children, and older people. CONCLUSIONS: Guidelines available early in the covid-19 pandemic had methodological weaknesses and neglected vulnerable groups such as older people. A framework for development of clinical guidelines during public health emergencies is needed to ensure rigorous methods and the inclusion of vulnerable populations. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020167361.

19 (care adj2 (standard or path or paths or pathway or pathways or map or maps or plan or plans)).ti,ab,kf,kw. (56205) 20 (algorithm* adj2 (screening or examination or test or tested or testing or assessment* or diagnosis or diagnoses or diagnosed or diagnosing or pharmacotherap* or therap* or treatment* or intervention*)).ti,ab,kf,kw. (16631) 21 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 27 (ebola* or ebov or marburg* or lassa* or CCHF or "crimean-congo*" or "congo virus" or (crimean adj2 (hemorrhagic or haemorrhagic)) or "rift valley*" or RVF 18 (care adj2 (standard or path or paths or pathway or pathways or map or maps or plan or plans)).ti,ab,kw. (99334) 19 (algorithm* adj2 (screening or examination or test or tested or testing or assessment* or diagnosis or diagnoses or diagnosed or diagnosing or pharmacotherap* or therap* or treatment* or intervention*)).ti,ab,kw. (24363) 20 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 29 ("middle east* respiratory syndr*" or MERS-CoV or "novel CoV*" or "novel betacoronavirus" or "novel coronavirus*" or ("middle east" adj3 (coronavirus* or cov or betacoronavirus*)) or (MERS adj3 (coronavirus* or cov or betacoronavirus*)) or "mers-coronavirus" or "mers cov" or merscov).tw. 10 (care adj2 (standard or path or paths or pathway or pathways or map or maps or plan or plans)).ti,ab. (5259) 11 (algorithm* adj2 (screening or examination or test or tested or testing or assessment* or diagnosis or diagnoses or diagnosed or diagnosing or pharmacotherap* or therap* or treatment* or intervention*)).ti,ab. (1743) 12 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 (65662) 22 ("middle east* respiratory syndr*" or MERS-CoV or "novel CoV*" or "novel betacoronavirus" or "novel coronavirus*" or ("middle east" adj3 (coronavirus* or cov or betacoronavirus*)) or (MERS adj3 (coronavirus* or cov or betacoronavirus*)) or "mers-coronavirus" or "mers cov" or merscov).tw. 

Cluster 1 ( ( TITLE-ABS-KEY ( "clinical pathway*" OR "clinical protocol*" OR consensus OR guideline* OR "position statement*" OR "policy statement*" OR "practice parameter*" OR "best practice*" ) OR TITLE-ABS-KEY ( ( care W/2 ( standard OR path OR paths OR pathway OR pathways OR map OR maps OR plan OR plans ) ) ) OR TITLE-ABS-KEY ( ( algorithm* W/2 ( screening OR examination OR test OR tested OR testing OR assessment* OR diagnosis OR diagnoses OR diagnosed OR diagnosing ) ) ) OR TITLE-ABS-KEY ( ( algorithm* W/2 ( pharmacotherap* OR therap* OR treatment* OR intervention* ) ) ) OR TITLE ( standards OR recommendat* ) ) ) AND ( ( TITLE-ABS-KEY ( ( ( virus OR viral ) W/3 ( "hemorrhagic fever*" OR "haemorrhagic fever*" ) ) OR ebola* OR ebov* OR marburg* OR lassa ) OR TITLE-ABS-KEY ( cchf OR "crimean-congo*" OR "congo virus" OR ( crimean W/2 ( hemorrhagic OR haemorrhagic ) ) OR "rift valley" OR rvf ) ) ) Cluster 2 ( ( TITLE-ABS-KEY ( "clinical pathway*" OR "clinical protocol*" OR consensus OR guideline* OR "position statement*" OR "policy statement*" OR "practice parameter*" OR "best practice*" ) OR TITLE-ABS-KEY ( ( care W/2 ( standard OR path OR paths OR pathway OR pathways OR map OR maps OR plan OR plans ) ) ) OR TITLE-ABS-KEY ( ( algorithm* W/2 ( screening OR examination OR test OR tested OR testing OR assessment* OR diagnosis OR diagnoses OR diagnosed OR diagnosing ) ) ) OR TITLE-ABS-KEY ( ( algorithm* W/2 ( pharmacotherap* OR therap* OR treatment* OR intervention* ) ) ) OR TITLE ( standards OR recommendat* ) ) ) AND ( ( TITLE-ABS-KEY ( "middle east* respiratory syndr*" OR mers-cov OR "novel CoV*" OR "novel betacoronavirus" OR "novel coronavirus*" ) OR TITLE-ABS-KEY ( ( "middle east" W/3 ( coronavirus* OR cov OR betacoronavirus* ) ) OR ( mers W/3 ( coronavirus* OR cov OR betacoronavirus* ) ) OR "mers-coronavirus" OR "mers cov" OR merscov ) OR TITLE-ABS-KEY ( ( "wuhan flu" OR 2019-ncov ) ) OR TITLE-ABS-KEY ( h1n1 OR h5n1 ) OR TITLE-ABS-KEY ( "zoonotic influenza*" ) ) ) Cluster 3 ( ( TITLE-ABS-KEY ( "clinical pathway*" OR "clinical protocol*" OR consensus OR guideline* OR "position statement*" OR "policy statement*" OR "practice parameter*" OR "best practice*" ) OR TITLE-ABS-KEY ( ( care W/2 ( standard OR path OR paths OR pathway OR pathways OR map OR maps OR plan OR plans ) ) ) OR TITLE-ABS-KEY ( ( algorithm* W/2 ( screening OR examination OR test OR tested OR testing OR assessment* OR diagnosis OR diagnoses OR diagnosed OR diagnosing ) ) ) OR TITLE-ABS-KEY ( ( algorithm* W/2 ( pharmacotherap* OR therap* OR treatment* OR intervention* ) ) ) OR TITLE ( standards OR recommendat* ) ) ) AND ( TITLE-ABS-KEY ( henipavirus OR nipah OR hendra OR monkeypox OR "monkey pox" OR chikungunya OR "Severe Fever with Thrombocyto* Syndrome" OR sfts OR plague OR "black death" OR "pathogen x" ) ) Web of Science Core Collection #1 TOPIC: ("clinical pathway*" OR "clinical protocol*" OR consensus OR guideline* OR "position statement*" OR "policy statement*" OR "practice parameter*" OR "best practice*" OR CPG OR CPGs) OR TOPIC: ((care near/2 (standard or path or paths or pathway or pathways or map or maps or plan or plans))) OR TOPIC: ((algorithm* near/2 (screening or

middle east* respiratory syndr*" or MERS-CoV or "novel CoV*" or "novel betacoronavirus" or "novel coronavirus*" or ("middle east" adj3 (coronavirus* or cov or betacoronavirus*)) or (MERS adj3 (coronavirus* or cov or betacoronavirus*)) or "mers-coronavirus" or "mers cov" or merscov).tw. (2593)

examination or test or tested or testing or assessment* or diagnosis or diagnoses or diagnosed or diagnosing))) OR TOPIC: ((algorithm* near/2 (pharmacotherap* or therap* or treatment* or intervention*))) OR TITLE: (standards OR recommendat*) #2 TOPIC: (((virus or viral) near/3 ("hemorrhagic fever*" OR "haemorrhagic fever*")) OR ebola* OR ebov* OR marburg* OR lassa OR CCHF or "crimean-congo*" or "congo virus" or (crimean near/2 (hemorrhagic or haemorrhagic)) OR "rift valley" OR RVF) #3 TOPIC: ("middle east* respiratory syndr*" or MERS-CoV or "novel CoV*" or "novel betacoronavirus" or "novel coronavirus*") OR TOPIC: (("middle east" near/3 (coronavirus* or cov or betacoronavirus*)) or (MERS near/3 (coronavirus* or cov or betacoronavirus*)) or "mers-coronavirus" or "mers cov" or merscov) OR TOPIC: (("wuhan flu" or 2019-nCoV)) OR TOPIC: (h1n1 or h5n1) OR TOPIC: ("zoonotic influenza*") #4 TOPIC: (Henipavirus OR nipah or hendra or monkeypox or "monkey pox" OR Chikungunya OR "Severe Fever with Thrombocyto* Syndrome" OR SFTS OR plague OR "black death" OR "pathogen x") #5 #2 AND #1 #6 #3 AND #1 #7 #4 AND #1The WHO Global Index Medicus Regional Libraries https://pesquisa.bvsalud.org/gim/?lang=en Cluster 1 (tw:("clinical path*" OR "clinical protocol*" or "critical path*" OR "critical protocol*" OR "practice path*" OR "practice protocol*" OR consensus OR guideline* OR standards OR "position statement*" OR "policy statement*" OR "practice parameter*" OR "best practice*" OR CPG OR CPGs OR "care standard" OR "care path*" OR "care map*" OR "care plan*" OR algorithm*)) AND (tw:(("viral hemorrhagic fever*" or "hemorrhagic fever* virus*" OR "viral haemorrhagic fever*" or "haemorrhagic fever* virus*" OR ebola* OR ebov* OR marburg* OR lassa OR CCHF or "crimean-congo*" or "congo virus" or "crimean hemorrhagic" or "crimean haemorrhagic" OR "rift valley" OR RVF))) Cluster 2 (tw:("clinical path*" OR "clinical protocol*" or "critical path*" OR "critical protocol*" OR "practice path*" OR "practice protocol*" OR consensus OR guideline* OR standards OR "position statement*" OR "policy statement*" OR "practice parameter*" OR "best practice*" OR CPG OR CPGs OR "care standard" OR "care path*" OR "care map*" OR "care plan*" OR algorithm*)) AND (tw:(("middle east* respiratory syndr*" or MERS-CoV or "novel CoV*" or "novel betacoronavirus" or "novel coronavirus*") or ("middle east" and (coronavirus* or cov or betacoronavirus*)) or (MERS near/3 (coronavirus* or cov or betacoronavirus*)) or "mers-coronavirus" or "mers cov" or merscov or ("wuhan flu" or 2019-nCoV) or h1n1 or h5n1 or "zoonotic influenza*")) Cluster 3 (tw:("clinical path*" OR "clinical protocol*" or "critical path*" OR "critical protocol*" OR "practice path*" OR "practice protocol*" OR consensus OR guideline* OR standards OR "position statement*" OR "policy statement*" OR "practice parameter*" OR "best practice*" OR CPG OR CPGs OR "care standard" OR "care path*" OR "care map*" OR "care plan*" OR algorithm*)) AND (tw:(Henipavirus OR nipah or hendra or monkeypox or "monkey pox" OR Chikungunya OR "Severe Fever with Thrombocyto* Syndrome" OR SFTS OR plague OR "black death" OR "pathogen x")) Google Scholar -Screen the first 10 pages of results Sorted by relevance:

Cluster 1 (guideline|consensus|standards|"clinical path*"|"clinical protocol*"|"practice path*"|"position statement*"|"policy statement*"|"best practice*")("viral hemorrhagic fever"|ebola*|ebov*|lassa|Marburg|CCHF|Crimean-congo|"congo virus*"|"rift valley") https://scholar.google.co.uk/scholar?hl=en&as_sdt=0%2C5&q=%28guideline%7Cconsensus %7Cstandards%7C%22clinical+path*%E2%80%9D%7C%22clinical+protocol*%22%7C%2 2practice+path*%22%7C%22position+statement*%22%7C%22policy+statement*%22%7C %22best+practice*%22%29%28%22viral+hemorrhagic+fever%22%7Cebola*%7Cebov*%7 Classa%7CMarburg%7CCCHF%7CCrimean-congo%7C%22congo+virus*%22%7C%22rift+valley%22%29&btnG=Cluster 2 (guideline|consensus|standards|"clinical path*"|"clinical protocol*"|"practice path*"|"position statement*"|"policy statement*"|"best practice*")("middle east resp* syndrome*"|mers*|"novel coronavirus*"|"middle east coronavirus*"|2019-nCoV|h1n1|h5n1|"zoonotic influenza*") https://scholar.google.co.uk/scholar?hl=en&as_sdt=0%2C5&q=%28guideline%7Cconsensus %7Cstandards%7C%22clinical+path*%E2%80%9D%7C%22clinical+protocol*%22%7C%2 2practice+path*%22%7C%22position+statement*%22%7C%22policy+statement*%22%7C %22best+practice*%22%29%28%22middle+east+resp*+syndrome*%22%7Cmers*%7C%2 2novel+coronavirus*%22%7C%22middle+east+coronavirus*%22%7C2019-nCoV%7Ch1n1%7Ch5n1%7C%22zoonotic+influenza*%22%29&btnG=Cluster 3 (guideline|consensus|standards|"clinical path*"|"clinical protocol*"|"practice path*"|" policy statement*"|"best practice*")(henipavirus|nipah|hendra|monkeypox|chickungunya|"severe fever with thrombocyte* syndrome"|sfts|"black death"|plague|"pathogen x") https://scholar.google.co.uk/scholar?hl=en&as_sdt=0%2C5&q=%28guideline%7Cconsensus %7Cstandards%7C%22clinical+path*%E2%80%9D%7C%22clinical+protocol*%22%7C%2 2practice+path*%22%7C%22+policy+statement*%22%7C%22best+practice*%22%29%28h enipavirus%7Cnipah%7Chendra%7Cmonkeypox%7Cchickungunya%7C%22severe+fever+ with+thrombocyte*+syndrome%22%7Csfts%7C%22black+death%22%7Cplague%7C%22p athogen+x%22%29&btnG=